SIT Laboratorio Farmaceutico acquires NATIFAR and NATIMED from Laboratorios BIAL
SIT Laboratorio Farmaceutico (hereafter “SIT”) is pleased to announce the acquisition of Natifar and Natimed brands from Laboratorios BIAL, S.A, a Spanish affiliate of BIAL Group (BIAL), as a result of the agreement signed on October 25th, 2022.
Both products are indicated to prevent disorders in cases of Iodine deficiency in pregnant period and as a prophylactic in development CNS deficiencies in the foetus. Both are Prescription products.
The acquisition of Natifar and Natimed supports the Gynaecological area of SIT and represent a notable enhancement for SIT in the Spanish market.
Either products will be distributed by SIT’s Spanish affiliate DESMA Laboratorio Farmacéutico, which already include in its Spanish portfolio well-known brands in different therapeutic areas like Akineton, Hemicraneal and Proctolog.
SIT is an Italian based pharmaceutical group with presence in 50 countries which develops, produces and commercializes more than 75 branded pharmaceutical products, Medical Devices and Food supplements.
About SIT Laboratorio Farmaceutico
SIT Group is a family-owned international pharmaceutical company, based in Italy since 1927, and today is an international pharmaceutical group with more than 90 years of experience and a recent history of prestigious acquisitions and global expansion. SIT Group is a reliable preferred acquirer for pharma businesses choosing to divest their “mature,” “established” or “tail” off-patent branded medicines.
In its manufacturing plants, SIT continue the high-quality manufacturing and management of the medicines, aspiring to breathe new life into medicines, investing in them to renew the lifecycle and give new stability and sustainability over the long-term. For more information please visit www.sit-farmaceutici.com